KEI Comment on the Reduction of Number of Days the Public Can Comment on a Prospective NIH Exclusive Patent License

The National Institute of Health (NIH) recently held an all-day workshop titled, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.” KEI Director James Love participated in the July 31st workshop, speaking on the panel on “How NIH… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

KEI Letter to US House Oversight Committee on NIH Misconduct and Lack of Transparency

On July 22, 2019, Knowledge Ecology International submitted a letter to the US House of Representative’s Committee on Oversight and Reform regarding the National Institutes of Health’s (NIH) lack of transparency in its exclusive licensing processes. Prior to executing an… Continue Reading